The Manufacturers Life Insurance Company lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 4.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,364,482 shares of the biopharmaceutical company's stock after selling 148,253 shares during the quarter. The Manufacturers Life Insurance Company owned 0.06% of Pfizer worth $81,017,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares in the last quarter. State Street Corp increased its holdings in Pfizer by 0.5% during the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company's stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC increased its holdings in Pfizer by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares during the last quarter. Morgan Stanley raised its position in shares of Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $1,830,986,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on PFE shares. Guggenheim dropped their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research note on Friday, August 7th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. JPMorgan Chase & Co. reduced their price target on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 8th. Citigroup boosted their price objective on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 29th. Finally, UBS Group reaffirmed a "neutral" rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.28.
Read Our Latest Report on PFE
Pfizer Stock Up 2.0%
Shares of NYSE:PFE opened at $28.53 on Wednesday. The company's fifty day moving average is $25.39 and its two-hundred day moving average is $26.27. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The stock has a market capitalization of $162.60 billion, a price-to-earnings ratio of 37.54 and a beta of 0.34.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.
Pfizer Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.0%. Pfizer's dividend payout ratio is 226.32%.
About Pfizer
(
Free Report)
Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
